Physicians' Academy for Cardiovascular Education

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Postive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

More intelligent intervention through more strategic use of CV biomarkers

3' education - May 28, 2019 - Maastricht, The Netherlands

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Factor Xa inhibitor effective and safe in AF patients with liver disease

Literature - July 23, 2019 - Qamar A, et al. - J Am Coll Cardiol 2019

In a subanalysis of the ENGAGE AF-TIMI 48 study, efficacy and safety of high dose edoxaban was similar in AF patients with and without liver disease.

Systolic and diastolic hypertension independently associated with CV outcomes

Literature - July 22, 2019 - Flint AC et al. - N Engl J Med 2019

In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.

During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD
Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.

Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD
Lp(a) is one of the most important genetically determined risk factors for CVD. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which is associated with reduced Lp(a) concentrations and lower CVD risk.

Lp(a) meeting Lp(a) is one of the most important genetically determined risk factors for CVD. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which is associated with reduced Lp(a) concentrations and lower CVD risk.

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the. mangement of CKD with resistant hypertension.

Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD
Elisa Waldmann shows prospective data on reduced CV event rates after initiation of Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after initiation of Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
The Copenhagen General Population Study investigated the prevalence of FH based on LDL-c levels after adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares the results and possible ways to interpret these results.

Lp(a) meeting The Copenhagen General Population Study investigated the prevalence of FH based on LDL-c levels after adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares the results and possible ways to interpret these results.

FDA Fast Track designation for development of SGLT2i therapy for chronic heart failure

News - July 4, 2019

The designation is granted for the ongoing EMPEROR program, which evaluates treatment with empagliflozin for the reduction of the risk of CV death and hospitalisation for HF in chronic HFrEF and HFpEF.

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD
Prof. Agarwal discusses the current standard of care  in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

ERA-EDTA 2019 Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?

The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?